Page last updated: 2024-10-30

lomefloxacin and Lung Diseases, Obstructive

lomefloxacin has been researched along with Lung Diseases, Obstructive in 1 studies

lomefloxacin: structure given in first source
lomefloxacin : A fluoroquinolone antibiotic, used (generally as the hydrochloride salt) to treat bacterial infections including bronchitis and urinary tract infections. It is also used to prevent urinary tract infections prior to surgery.

Lung Diseases, Obstructive: Any disorder marked by obstruction of conducting airways of the lung. AIRWAY OBSTRUCTION may be acute, chronic, intermittent, or persistent.

Research Excerpts

ExcerptRelevanceReference
" Compared with the data reported for young adults, the elimination half-life (12."5.28Steady-state pharmacokinetics and sputum penetration of lomefloxacin in patients with chronic obstructive pulmonary disease and acute respiratory tract infections. ( Glerum, JH; Hoepelman, AI; Kovarik, JM; Rozenberg-Arska, M; Sips, PA; Smit, JM; Verhoef, J, 1992)
" Compared with the data reported for young adults, the elimination half-life (12."1.28Steady-state pharmacokinetics and sputum penetration of lomefloxacin in patients with chronic obstructive pulmonary disease and acute respiratory tract infections. ( Glerum, JH; Hoepelman, AI; Kovarik, JM; Rozenberg-Arska, M; Sips, PA; Smit, JM; Verhoef, J, 1992)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kovarik, JM1
Hoepelman, AI1
Smit, JM1
Sips, PA1
Rozenberg-Arska, M1
Glerum, JH1
Verhoef, J1

Other Studies

1 other study available for lomefloxacin and Lung Diseases, Obstructive

ArticleYear
Steady-state pharmacokinetics and sputum penetration of lomefloxacin in patients with chronic obstructive pulmonary disease and acute respiratory tract infections.
    Antimicrobial agents and chemotherapy, 1992, Volume: 36, Issue:11

    Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Chronic Disease; Female; Fluoroquinolones; Humans; L

1992